Sulfacetamide

Quick links to important sections

Sulfacetamide

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfacetamide

Property Description
Active Ingredient Sulfacetamide (INN)
Form Ophthalmic solution/ointment, topical lotion/wash
Pharmacological Class Sulfonamide Antibiotic (Sulfa Drug)
Common Use Control localized bacterial infections
Origin Synthetic

What Type of Medicine is Sulfacetamide? (Classification and Origin)

Sulfacetamide is a synthetic pharmaceutical compound that is classified pharmacologically as a sulfonamide antibiotic, commonly recognized as a sulfa drug. It belongs to the broader category of antibacterial agents and is characterized by its specific chemical structure, N^1-[(4-aminophenyl)sulfonyl]acetamide. Sulfacetamide is used for specific localized infections, serving as an antimicrobial agent. This classification is clinically recognized for providing highly localized antibacterial control in situations where susceptible organisms are present.


Understanding Sulfacetamide’s General Purpose and Delivery

  1. The general purpose of Sulfacetamide is to inhibit the proliferation of susceptible bacteria where it is applied, thereby controlling the infection and aiding the body's resolution process. Its function is bacteriostatic, meaning it stops bacterial growth rather than directly killing the microorganisms. Sulfacetamide Sodium is recognized as a well-established sulfonamide antibacterial agent. This classification confirms its defined purpose as a primary agent for managing localized bacterial concerns, such as controlling an infection on the ocular surface or the skin.
  2. Due to its targeted action, Sulfacetamide is strictly limited to the topical route of administration, delivered through specialized ophthalmic and dermatologic preparations.

Active Ingredient and Preparation Base (Composition Overview)

  1. The preparation's sole active ingredient is Sulfacetamide (INN). This compound's efficacy is based on disrupting the bacteria’s need for folic acid—a compound essential for synthesizing genetic material—through a competitive inhibition process.
  2. Sulfacetamide is available under various topical dosage forms, including an ophthalmic solution (eye drops), an ophthalmic ointment, and a topical lotion or wash for dermatologic use. These are compounded using bases such as aqueous solutions or hydrophilic ointment bases to optimize contact with the affected tissue.

Regulatory References

  1. United States National Library of Medicine (NLM)
  2. NIH MedlinePlus

What side effects are possible with Sulfacetamide?

Possible Side Effects and Safety Information

The officially documented adverse effects of Sulfacetamide, a sulfonamide antibiotic, are categorized based on their severity and the affected organ system, reflecting the regulatory standards for all sulfa drugs.


Local and Common Adverse Reactions

The most commonly reported effects are local reactions at the site of application. These generally include stinging, burning, and irritation in the eye for ophthalmic use, or reddening and scaling of the epidermis for dermatologic use. Prolonged use of the preparation may lead to an overgrowth of nonsusceptible organisms, including fungi, a documented risk for antibacterial agents.


Systemic and Serious Adverse Reactions

Sulfonamide hypersensitivity, a risk associated with this drug class, is officially documented as leading to rare but severe systemic reactions. These effects are grouped across major body systems, including:

  • Skin and Subcutaneous Tissue Disorders: Severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which have been reported to result in fatalities.
  • Blood and Lymphatic System Disorders: Serious blood dyscrasias like aplastic anemia and agranulocytosis.
  • Hepatobiliary Disorders: Instances of severe liver damage, including fulminant hepatic necrosis.

Official Safety Constraints and Special Populations

Safety labeling specifies constraints on the use of Sulfacetamide. It is officially contraindicated in patients with a known or suspected hypersensitivity to any sulfonamide and in individuals with kidney disease.

For special populations, the safety profile is limited. Safety and effectiveness have not been established for pediatric patients under the age of 12 years for dermatologic products. Furthermore, the risk of systemic absorption is increased when the medication is applied to large, infected, abraded, or denuded areas of the skin, potentially leading to systemic effects.

Overdose and Emergency Response

The official regulatory guidance for Sulfacetamide overdose focuses on the potential for systemic sulfonamide toxicity following excessive topical application or accidental oral ingestion. Manifestations resulting from systemic absorption may include nausea, vomiting, diarrhea, dizziness, and drowsiness. Severe, life-threatening outcomes are documented, with particular focus on the risk of blood dyscrasias (such as agranulocytosis and aplastic anemia) and the potential for crystalluria, a condition associated with acute renal injury. Locally, overdose may present as pronounced stinging or increased discharge.

Due to the critical nature of these documented systemic risks, regulatory authorities mandate that individuals seek immediate medical attention and contact emergency services or a Poison Control Center whenever an overdose is suspected. The official management approach is defined as strictly symptomatic and supportive treatment. The prescribing information specifies that no specific antidote is known. Required supportive care procedures include hematological monitoring and the assessment of renal function. Furthermore, management may necessitate the use of forced oral fluids to manage the risk of renal complications. This profile defines the conditions under which urgent medical help is required.

Therapeutic Uses of Sulfacetamide

What Sulfacetamide Treats: Main Uses and Benefits

The medication Sulfacetamide is commonly used in contexts involving inflammatory or irritative processes that may be complicated by bacteria. It is generally relevant in clinical contexts where symptoms that interfere with daily functioning are present on the surface of the eye or skin. It is applied across therapeutic domains where additional symptomatic support is needed.


Symptom Management and Therapeutic Support

Sulfacetamide is commonly used to help with superficial bacterial eye infections such as acute conjunctivitis, specific forms of keratitis, and blepharitis. It helps address symptom clusters that include ocular redness, eyelid swelling, and the presence of infectious discharge. In dermatology, its application is relevant across conditions characterized by periods of heightened symptoms like acne vulgaris, papulopustular rosacea, and seborrheic dermatitis, where it assists in addressing symptom clusters related to inflammatory lesions and associated redness.

The overall benefit is supportive relief. For the patient, this means:

“The application provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.”

This supportive relief contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Inflammatory Symptoms
Sulfacetamide supports the management of acute symptoms, typically focusing on localized discomfort associated with redness, swelling, and lesions related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Sulfacetamide eligibility is strictly defined by regulatory authorities and centers on patient sensitivity and age. The medicine is formally contraindicated and must not be used by individuals with known hypersensitivity to sulfonamides or any other ingredient in the specific preparation. This exclusion is absolute across all ophthalmic and topical formulations.

Eligibility is restricted for certain age groups due to insufficient data:

Population Group Regulatory Status
Infants under 2 months Contraindicated (Ophthalmic use)
Children under 12 years Use not established (Topical lotions)

Additionally, use is not recommended for patients with comorbidities such as kidney disease, which is a formal contraindication when using certain combination products containing sulfur. For pregnant women, Sulfacetamide is classified as Pregnancy Category C. Use is conditional, permitted only if the potential benefit warrants the potential risk. Nursing mothers are advised to use caution, as regulatory information recommends a decision to either discontinue the medicine or discontinue nursing.

What should I know about interactions with other medicines?

The interaction profile for topical Sulfacetamide is highly specific, focusing primarily on chemical incompatibilities and risk factors related to systemic exposure rather than typical drug-drug metabolic interactions. No specific enzyme-mediated or transporter-based interactions with co-administered medicines are specified in the official regulatory documentation.

Documented Interaction Restrictions

Official regulatory documents establish formal prohibitions and risk factors related to this product.

Interaction Type Interacting Substance/Condition Description
Chemical Incompatibility Silver Preparations Co-administration is formally prohibited due to documented chemical incompatibility between Sulfacetamide and silver preparations, such as silver nitrate.
Systemic Exposure Risk Compromised Skin Barrier The potential for systemic absorption is increased when the product is applied to large, abraded, infected, denuded, or severely burned skin areas. This modification in exposure heightens the risk of systemic effects associated with sulfonamides.
Population Restriction Kidney Disease The product is formally contraindicated in patients with known kidney disease. This restriction is based on the heightened risk of drug accumulation and potential toxicity, even from minimal systemic absorption.

Interaction Classifications

Regulatory documentation classifies the interaction with silver preparations as a Formal Contraindication. The overall interaction structure is defined by avoiding incompatible substances and restricting use based on the integrity of the application site and the patient's internal clearance capacity.

Mechanism of Action

How Sulfacetamide Works: Mechanism of Action

Sulfacetamide's action is defined by its role as a competitive inhibitor within the bacterial metabolic pathway. The drug is structurally analogous to para-aminobenzoic acid (PABA), an essential substrate required by bacteria. Sulfacetamide competes with PABA to bind to the active site of the bacterial enzyme Dihydropteroate Synthase (DHPS). This binding physically blocks the enzyme, thereby preventing the crucial first step in the synthesis of dihydrofolic acid, and consequently, tetrahydrofolic acid (folate).

This folate deprivation initiates a downstream cascade: the resulting lack of folate, an essential cofactor, prevents the synthesis of purines and pyrimidines, the fundamental molecular components of DNA and RNA. The inability to produce new nucleic acids leads directly to the cessation of bacterial replication and growth (a bacteriostatic effect) at the local site. This mechanism exploits a fundamental metabolic difference, as DHPS is absent in human cells, which obtain pre-formed folate through the diet.

Dosage and Administration Information

Sulfacetamide is administered exclusively via the topical route, utilizing distinct ophthalmic and dermatologic preparations. Usage protocols vary based on the site of application.

Administration Routes and Forms

The medication is available as an Ophthalmic Solution 10% and Ointment 10% for use in the eyes, and as various Topical Preparations (lotions, washes, suspensions) for external skin application. The dermatologic forms are strictly labeled FOR EXTERNAL USE ONLY. For some topical suspensions, the container must be shaken well before using to ensure uniform application.

Dosing Frequency and Duration

For acute ocular applications, the regimen is frequent and short-term. The Ophthalmic Solution is typically instilled as one to two drops into the conjunctival sac every two to three hours initially. The dosage interval is then tapered (lengthened) as the condition responds, over a standard course of seven to ten days. The Ophthalmic Ointment is applied as a small ribbon every three to four hours and at bedtime.

Dermatologic preparations are applied in a thin film once to twice daily. Following an initial treatment period, the frequency may be lengthened to a maintenance schedule.

Population and Procedural Rules

The safety and effectiveness of the ophthalmic forms have not been established for infants under two months of age. For proper use, patients must not allow the tip of the container to touch the eye, eyelid, or any other surface to prevent contamination. Additionally, when used as an adjunct for Trachoma, the topical ophthalmic administration must be accompanied by systemic administration of a sulfonamide.

Recent Clinical Evidence

Overview of Studies for Topical Sulfacetamide

This overview describes the types of clinical studies that have evaluated topical Sulfacetamide formulations, detailing the areas of research, the outcomes monitored, and what the evidence suggests about the current state of knowledge. This information does not provide clinical guidance or treatment recommendations.


Evidence Base for Dermatologic Use in Acne Vulgaris

Some research for topical Sulfacetamide in acne vulgaris involves randomized, double-blind, parallel-group clinical studies. These studies were used in research exploring how symptoms change over time, focusing on the count of inflammatory lesions (such as papules and pustules) and assessing the overall presentation using a physician's Global Assessment score. Findings describe patterns observed in the studies over the short follow-up duration. The evidence is limited by the fact that many comparative trials have focused on Sulfacetamide in combination with Sulfur.

Evidence Base for Dermatologic Use in Papulopustular Rosacea

Some research for topical Sulfacetamide in papulopustular rosacea includes randomized, vehicle-controlled trials and comparative studies. This research examined outcomes linked to inflammatory or irritative states in adults, such as the count of inflammatory lesions and changes in scores related to facial erythema (redness). The follow-up durations were limited, with most comparative evidence lasting 12 weeks or less.

Evidence Base for Ophthalmic Use in Superficial Eye Infections

The evidence base for topical Sulfacetamide ophthalmic preparations primarily consists of historical data, and regulatory approval relies significantly on the established classification of the sulfonamide drug class as an antibacterial agent. Research has also examined the drug's activity through in vitro studies, which reported antimicrobial activity against specific, susceptible bacterial organisms.


What Remains Uncertain About the Research

A key research limitation frame is that the evidence quality varies across studies, with many modern clinical trials for dermatologic use was observed in a combination product, leading to ongoing uncertainty about the isolated performance of Sulfacetamide alone. Furthermore, comparative evidence is lacking against the full range of newer topical anti-infective and anti-inflammatory agents. Finally, data for certain groups remain insufficient, such as for very young children (infants below the age of two months), where effectiveness has not been established in specific studies.

Key Studies & References

  1. Sulfacetamide Ophthalmic Solution: Drug Information
  2. Sulfonamides (Ophthalmic) Drug Monograph: Classification and Historical Use

Frequently Asked Questions (FAQ)

Common questions about Sulfacetamide (FAQ)


Q: Is it normal to feel a stinging sensation when first applying Sulfacetamide?

Official regulatory documentation lists a stinging, burning, or irritation sensation as a frequently reported local reaction at the site of application for both the eye and skin forms of this medication. This effect is commonly noted when using the product.


Q: Does Sulfacetamide make your skin more sensitive to the sun?

Authoritative patient information resources mention that this medication may increase your skin’s sensitivity to the sun. This potential for photosensitivity is sometimes accompanied by information suggesting the use of protective clothing and sunscreen if sun exposure is anticipated.


Q: Can Sulfacetamide be used by elderly patients?

Official information places specific age-based restrictions only on the use in infants under two months (for the eye drops) and children under 12 years (for topical skin products). No specific warnings or dosage adjustments related to age are documented for the general elderly population.


Q: Why is Sulfacetamide sometimes combined with other ingredients like sulfur?

In many commercial preparations, Sulfacetamide is combined with sulfur. Regulatory documents for these combination products note that sulfur has 'keratolytic' effects, meaning it helps to loosen and shed the outer layer of skin. This action is generally understood to complement Sulfacetamide's bacteriostatic (bacteria-stopping) effect to address multiple aspects of skin conditions like acne.


Q: Does the form of Sulfacetamide (lotion, wash, solution) change its effectiveness?

The specific form of Sulfacetamide is tied to the intended site and method of application. Official documents define distinct forms—such as solutions and ointments for the eye, and lotions or washes for the skin—to ensure proper delivery, contact time, and area of coverage for the specific condition being addressed.


Q: What are the general guidelines for storing Sulfacetamide products?

According to official documentation, the medication must be stored at controlled room temperature. It is a mandatory requirement to protect the product from both freezing and excessive heat. For stability and safety, the container should also be kept tightly closed and protected from light.


Q: Why does Sulfacetamide seem to come in so many different forms?

Sulfacetamide is formulated into separate ophthalmic preparations (solutions and ointments) for use in the eye, and topical preparations (lotions, washes, and suspensions) for use on the skin. This variety of forms is necessary to ensure the drug can be applied safely and effectively to the specific infected area.


Q: Does Sulfacetamide treat acne or just prevent it?

Sulfacetamide is defined as a bacteriostatic agent, which means its action is to stop the growth and multiplication of susceptible bacteria. For conditions like acne, this action helps to control the local bacterial population implicated in the condition, managing the infection rather than preventing all future breakouts.


Q: What is the difference between sulfacetamide and sulfur face washes?

The official classification of Sulfacetamide is a sulfonamide antibacterial agent, which targets and controls bacteria. Sulfur, when included, is typically a secondary ingredient added for its keratolytic (exfoliating) properties that help shed dead skin, but it is not the primary antibacterial component.


Q: Is Sulfacetamide prescribed for styes or pink eye?

The ophthalmic solution is formally indicated for the treatment of superficial ocular infections caused by susceptible bacteria. This use is associated in patient information resources with treating superficial conditions like bacterial conjunctivitis (often called pink eye).


Q: Is Sulfacetamide commonly used for skin conditions other than acne?

Yes, official regulatory documents indicate that in addition to treating acne vulgaris and acne rosacea, topical Sulfacetamide preparations are formally indicated for other skin conditions, including seborrheic dermatitis and secondary bacterial skin infections.


Q: What signs should I look for that might indicate a bad reaction to Sulfacetamide?

Official product labeling indicates that use should be discontinued and guidance sought promptly if signs of a serious reaction develop. These signs may include the development of a rash, fever, arthritis, or sores appearing in the mouth.


Q: Is it true that Sulfacetamide can cause discoloration of clothing or hair?

Regulatory documentation for some topical washes states that a slight yellowish discoloration of white fabrics may occur if excessive amounts of the product contact the material. This discoloration is noted as being removed by ordinary laundering.


Q: What does it mean if Sulfacetamide is described as a 'sulfonamide'?

Sulfonamide refers to the formal pharmacological class of medicine to which Sulfacetamide belongs, also commonly referred to as a 'sulfa drug.' This classification defines it as an antibacterial agent that works by interfering with the bacteria’s natural process of making the folic acid necessary for their growth.


Q: Can Sulfacetamide cause problems if it gets into your eyes or mouth?

For the topical preparations intended for the skin, regulatory patient information explicitly instructs users to avoid contact with the eyes, lips, and other mucous membranes. If accidental contact with these areas occurs, the general instruction is to rinse the area with water.


Q: Can Sulfacetamide be used on parts of the body other than the face?

The topical preparations are indicated for skin conditions such as acne and seborrheic dermatitis. Administration instructions refer to applying the medicine to the affected areas, which is not specifically restricted to the face, provided the application site is intact.


Q: Does Sulfacetamide treat fungal infections as well as bacterial ones?

Sulfacetamide is classified solely as a sulfonamide antibacterial agent. The official labeling contains a precaution that prolonged use of any antibacterial agent may lead to an overgrowth of organisms that are not susceptible to the drug, including fungi.


Q: What happens if you stop using Sulfacetamide suddenly?

Sulfacetamide is used for the long-term topical control of certain skin conditions. While there is no direct instruction for stopping, the regulatory text suggests that if the skin condition recurs after stopping therapy, application of the product may be reinitiated.


Q: Does Sulfacetamide interact with common non-prescription pain relievers?

Official regulatory documentation specifies a formal chemical incompatibility only with silver preparations. It does not specify other common drug-drug metabolic interactions with co-administered systemic medicines, such as non-prescription pain relievers.


Q: Why is it necessary to complete the full course of Sulfacetamide?

The need to complete the full course of therapy, when prescribed, relates to the underlying principle of controlling the local bacterial population and potentially reducing the development of bacterial resistance, as noted in the regulatory text for antibacterial agents.


Q: Does the effectiveness of Sulfacetamide decrease over time?

The official labeling for sulfonamides, including Sulfacetamide, notes that bacterial resistance can develop over time. This means that the bacteria causing the infection could potentially become resistant to the drug’s effects.


Q: What is the generally accepted advice regarding using contact lenses while using the ophthalmic form?

The consumer information for the ophthalmic form generally states that contact lenses should not be worn while signs and symptoms of an eye infection are present. Guidance should be sought regarding when it is appropriate to resume wearing them.

How should Sulfacetamide be stored and disposed of?

How to Store and Dispose of Sulfacetamide?

Sulfacetamide sodium must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It is a mandatory requirement to protect the medication from freezing and from excessive heat.

Official Storage Conditions

Requirement Constraint
Temperature Controlled Room Temperature
Protection Protect from freezing and excessive heat
Container Keep tightly closed and protect from light
Safety Store out of the reach of children

For stability, the solution must be inspected for changes; the label states that the product should not be used if the solution has darkened.

Disposal

Disposal of unused or expired sulfacetamide must be carried out according to local regulations. Patients are instructed to consult with a pharmacist or local waste disposal company for guidance on the proper procedure for discarding the medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulfacetamide found in:

A-Z Index: